Bristol-Myers Squibb Co
BMY
View Detailed Chart
56.245USD
-0.475-0.84%
Market hours （ET）Quotes delayed by 15 min
114.51BMarket Cap
18.93P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.84%
5 Days
+4.27%
1 Month
+7.85%
6 Months
+20.98%
Year to Date
+4.27%
1 Year
-1.57%
View Detailed Chart
TradingKey Stock Score of Bristol-Myers Squibb Co
Currency: USD Updated: 2026-01-07Key Insights
Bristol-Myers Squibb Co's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 14 out of 158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 54.20.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bristol-Myers Squibb Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
48°C
Very Low
Very High
Negative
Bristol-Myers Squibb Co Highlights
StrengthsRisks
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 19.09, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.68B shares, decreasing 2.33% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 605.00 shares of this stock.
Analyst Rating
Based on
30
analysts
Hold
Current Rating
54.196
Target Price
+2.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Bristol-Myers Squibb Co Info
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Ticker SymbolBMY
CompanyBristol-Myers Squibb Co
CEOBoerner (Christopher S)
Websitehttps://www.bms.com
FAQs
What is the current price of Bristol-Myers Squibb Co (BMY)?
The current price of Bristol-Myers Squibb Co (BMY) is 56.245.
What is the symbol of Bristol-Myers Squibb Co?
The ticker symbol of Bristol-Myers Squibb Co is BMY.
What is the 52-week high of Bristol-Myers Squibb Co?
The 52-week high of Bristol-Myers Squibb Co is 63.330.
What is the 52-week low of Bristol-Myers Squibb Co?
The 52-week low of Bristol-Myers Squibb Co is 42.520.
What is the market capitalization of Bristol-Myers Squibb Co?
The market capitalization of Bristol-Myers Squibb Co is 114.51B.
What is the net income of Bristol-Myers Squibb Co?
The net income of Bristol-Myers Squibb Co is -8.95B.
Is Bristol-Myers Squibb Co (BMY) currently rated as Buy, Hold, or Sell?
According to analysts, Bristol-Myers Squibb Co (BMY) has an overall rating of Hold, with a price target of 54.196.
What is the Earnings Per Share (EPS TTM) of Bristol-Myers Squibb Co (BMY)?
The Earnings Per Share (EPS TTM) of Bristol-Myers Squibb Co (BMY) is 2.971.
Related Instruments
-2.39%
-0.82%
-3.68%
-0.79%
+1.17%
-0.28%
+1.79%
-3.21%
-2.74%
-0.22%
-2.92%
-0.45%
-0.79%
-2.08%
-0.20%
-0.41%
0.00%
+1.46%
-5.90%
